Cell and Gene Therapy 08/03/2017 Quantitative Understandings of Risk in Cell and Gene Therapies What is risk? How can we accurately understand risk and apply this understanding to inform solutions for investors? There are no easy answers to...
Immuno-oncology 06/03/2017 Systematic Automation of an Autologous Cellular Immunotherapy... As more and more approvals of immuno-oncology therapies become reality, how will these therapies be efficiently and sustainably scaled up and...
Cell and Gene Therapy 08/01/2017 Interview: market authorisation, HTA involvement in early drug... Dr Leeza Osipenko is Associate Director of NICE and works closely with EMA, MHRA, European HTA agencies and EUNETHTA. She chairs most of the...
